The issue regarding reimbursement standards set for pulmonary arterial hypertension drugs finally bore fruit three years after experts in Korea including the Korean Society of Cardiology, Korean Pulmonary Hypertension Society, The Korean Society of Hypertension, and The Korean Academy of Tuberculosis and Respiratory Diseases publicized the issue.

The accumulated academic evidence presented by the academic societies on how the active use of combination therapy in the early stages directly translates to improved prognosis has shifted the government to actively embrace the data.

According to societies including KSC on the 21st, the Ministry of Health and Welfare will be amending the standar